Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10735502 | 0.98 | MAPT (0.53) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL10712475 | 0.81 | MAPT (0.61) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL3239031 | 0.81 | KDM4E (0.54) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL4846705 | 0.81 | ALDH1A1 (0.44) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL4846697 | 0.81 | ALDH1A1 (0.44) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL2027674 | 0.80 | MAPT (0.47) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL24523710 | 0.79 | KDM4E (0.53) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL12523092 | 0.79 | KDM4E (0.53) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL102283 | 0.79 | KDM4E (0.53) | MAPTKDM4ENPC1RAB9ACASP3 | |
| SCHEMBL318526 | 0.79 | KDM4E (0.53) | MAPTKDM4ENPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688786-A2 | 1-THIOXO-2,4-DIHYDROTHIENO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRIMIDIN-5(1 H)-ONE DERIVATIVES AS ALLOSTERIC INHIBITORS OF THE POLO-LIKE KINASE 1 (PLK1) POLO BOX DOMAIN (PBD) FOR THE TREATMENT OF CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025040167-A1 | PHOSPHOINOSITIDE 3-KINASE ALLOSTERIC INHIBITOR FOR TREATING DISEASE RELATED TO PI3K REGULATION | 上海艾力斯医药科技股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| WO-2024206892-A2 | ALLOSTERIC INHIBITORS OF THE PLK1 POLO BOX DOMAIN, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-10-03 | — | — | WO | disclosed |
| CN-116023359-B | Synthesis method of aminothiophene compound and aminothiophene compound | 上海泰坦科技股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240043446-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | INTERVET INC. (US) | 2024-02-08 | — | — | US | disclosed |
| CN-117024441-A | MAT2A inhibitor | 武汉人福创新药物研发中心有限公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4259636-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | Intervet International B.V. (NL) | 2023-10-18 | — | — | EP | disclosed |
| CN-116888127-A | Tri-fused ring HPK1 inhibitor and application thereof | 轩竹生物科技股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-1326841-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SmithKline Beecham P.L.C. (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030904-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
| EP-0213450-B1 | Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1992-01-08 | — | — | EP | disclosed |
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | disclosed |
| US-4710506-A | Antihypertensive thienopyridines | THE BOOTS COMPANY PLC (GB) | 1987-12-01 | — | — | US | disclosed |
| US-4659707-A | ANTIULCER, ANTISECRETORY, ANTIMUSCARINIC AND/OR ANTISPASMODIC AGENTS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1987-04-21 | — | — | US | disclosed |
| EP-0213450-A2 | Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1987-03-11 | — | — | EP | disclosed |
| EP-0209977-A2 | Thienopyridones, processes and intermediates for their preparation and pharmaceutical compositions containing them | The Boots Company PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043446-A1 | ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE | DHODH, NISCH, DDT | MAPT 1851/4885KDM4E 1389/4885NPC1 3577/4885 |
| US-20240208952-A1 | THIOPHENE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | MAPT 2643/4885KDM4E 2930/4885NPC1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.